Resources

In this blog, Ivana Visnjic-Lynch, Marketing Manager at ZAGENO, discusses the race for breakthrough therapies and the need for  effective R&D spend management which enables technology to unlock the future.

In the last week, we have been hit by headlines that MSD plans to close its discovery research activities in London and that AstraZeneca is pausing investment due to the UK commercial environment and specifically in response to VPAG outcomes.

In this interview, we speak with Abby Clark, the BIA's Manufacturing Programme Manager, who shares her personal journey from a degree-level apprenticeship to a key policy role.

September has got off to a busy start at BIA, with significant raises, deals, expansion and M&A activity for members; welcoming our US counterparts to London, closely monitoring UK political shuffles and the party conference action as that kicks off with Reform and some unwelcome anti-vaccine misinformation.

In this blog, Paul Nelson, Corporate Foreign Exchange at Moneycorp, outlines the unpredictability of global markets and what this means for BIA members. 

In this blog, Elisa Petris, Partner at Syncona Investment Management Limited, and Emma Johnson, Senior Investment Manager – Life Sciences at the British Business Bank, write in their capacity as Co-founders of Invest in Equity. They share why they launched the initiative, the urgency of improving gender diversity in life science investment, and how a more inclusive ecosystem can drive stronger returns and better outcomes for patients.

In this blog, Alastair Hall, Hub Eurasia Director, FI Group, explores how Innovate UK Innovation Loans are helping biotech SMEs bridge the gap between research and commercialisation. He highlights why they are most effective when combined with other funding sources to build a resilient strategy for growth.

Shaun Grady is becoming BIA chair, effective from January 2026, in another week of innovation for our sector.

In our latest blog, Isabel Vincent, Market Development Manager at Firefinch Software, shares how the team is driving innovation with custom software, harnessing AI and exploring cutting-edge imaging technologies, helping to shape the future of biotech and MedTech.

In the third part of our series on Industrial Strategy, Lewis Miles and Maddie Cass provide a deep dive into the Digital and Technologies Sector Plan, analysing how these policies aim to foster growth in the UK's life sciences and engineering biology sectors. We also look forward to strengthening relations and gaining key insight from our US sister organisation with BIO's upcoming UK visit.

In the third instalment of our updates on new Government policy, Lewis Miles and Maddie Cass from BIA’s Policy and Public Affairs team take a deep dive into the Industrial Strategy and the Digital and Technologies Sector Plan, breaking down the implications for engineering biology and the wider life sciences sector.  

In this blog, Emma Lawrence, Head of Data Tech Policy and Public Affairs at BIA, explains why BIA is publishing a health data access industry checklist to support data access.

In this blog, Charlotte shares how her experience as a mentee on the BIA’s Women in Biotech mentoring programme helped her build confidence, embrace her leadership style, and navigate the challenges of a growing career in biotech. 

In the second instalment of our blog series on new government policy, Lewis Miles and Linda Bedenik examine the UK's Trade and National Security strategies and what they mean for biotech.

In a shifting global landscape, we break down how the UK's new Trade and National Security strategies aim to future-proof our biotech sector.

Call for BIA Board candidates. We are delighted to invite nominations from individuals interested in joining the BIA Board.

The BioIndustry Association (BIA) is now inviting applications for its 2026 Charity Partnership.

 In this blog, Abby Clark builds on a round table the BIA hosted with Chi Onwurah MP and Newcastle life science companies to explore the landscape and the drivers which make the sector strong, yet undervalued. 

In this blog, Martin Turner, Director of Policy and External Affairs at BIA, reflects on the long-anticipated Life Sciences Sector Plan and what it means for scaling UK biotech. This is the first in a series of blogs that will be released in the coming weeks.

In my final summer update as BIA CEO, I reflect on 12 amazing years and look ahead to my new role as Executive Chair of the Office for Life Sciences. This week we’ve also published our latest finance report, and we’re hiring - so if you’re looking for your next challenge, now’s the time to join Team BIA.